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Multiplicity of Depressive Episodes: 
Phenomenological and Neuroendocrine Correlates 
George N.M. Gurguis, James H. Meador-Woodruff, 
Roger F. Haskett, and John F. Greden 
Sixty-four patients with a Research Diagnostic Criteria (RDC) diagnosis of major de- 
pressive disorder were categorized into three groups based on their number of depressive 
episodes (DE): Gr I (1 DEp, n = 16, Gr 11 (2-4 DE), n = 25; and Gr Ill. (5 o'r more 
DE), n = 23. All patients were nonsuppressors after I m g  dexamethasone suppression 
test (DST) prior to the start of treatment. Patients were monitored during the course of 
their treatment using serial Hamilton Depression scores and post-DST plasma cortisol 
levels. A proportionately equai ~ number of patients in the three groups ~..,~a a favorable 
outcome, i.e., the number of depressive epdsodes did no~: predict recove~ 7. Despite fa- 
vorable clinical outcome, patients with kigher numbers ~f depressive episodes hoxl sig- 
nificantly higher post-DST plasma cortisc, l levels that were above the suppressive: range 
(greater than 5 ttg/dl). Patients with a higher number of depressive episodes had a 
significantly shorter duration of index episode and were younger at first depressive episode 
than patients in the other two groups. These results, however, were confounded with 
polarity, with a higher nv.mber @ bipolars in Gr iil than in the other two groups. Results 
are discussed in light of phezromenological a,Td psychoendocrine findings of earfier 
studies. 
Introduction 
The chronic, episodic, and recurrent nature of major depressive disorder represents a 
prominent feature, in its phenomenology. Therefore, studying the effect of time course 
on the phenomenology and neuroendocri~Jology of this illness could help further our 
understanding of the underlying pathopbysiological mechanisms and prognostic aspects 
of depression. Particularly relevant to ~he neuroendocrinology of depression is the reg- 
ulation of the hypothalamic-pituitary-adrenocortical (HPA) axis over the course of time. 
Hypothetically, the dysregulation of this system may change as the illness becomes 
progressively chronic. 
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Studies that have examined this longitudinal aspect showed ~h~.t non~uppression of 
plasma cortisol levels in response to dcxamethasone is state dependent (Can-oil et al. 
1976; Nuller and Ostroumova 1980; Greden et al. 1982, 1983; Gerkin et al. 1985). 
Reversion to a nonsuppressive status, reportedly heralded r¢lap~¢ (;-~ol,boer ct al. 1983), 
and a high degree of consistency in dexamethasone suppression test (DST) status across 
hospitalizations was reported (Brown and Quails 1982; Coryell and Scidesser 1983; 
Grunhaus et al. 1983; Yerevanian et al. 1984). Longitudinal follow-up during index 
depressive episode demonstrated that n~nsuppressor pat~en~s had gradual decreases ~JoL 
their post-DST plasma cortisol levels as they showed ~adual clinical improvement. This 
normalization process was observed with a variety of treatment modalities (Greden et al. 
1980; Goldberg 1980~ Gold et al. 19R0; Dysken et al. 1979; Papakostas et al. 1981; 
Holsboer et ai. 1982, 1983; Yerevanian et al. 1983; Albala and Greden 1980; Albala-et 
al. 1981; Rothschild and Schatzt,.erg 1982; Targum 1983). Yet, despite the close temporal 
rel~,tionship between clinical recovery and DST normalization, investigators documented 
a s~population of patients who maintained a nonsuppressor status after clinical recovery 
(Gr~den et al. 1983; Papakostas et al. 1981; Holsboer et ai. 1982, Targum 1983); these 
pat~a~nts were reportedly more prone to an earlier relapse (Greden et al. 1983; Holsboer 
et al. ~982; Targum 1983). It is not known if such failure to suppress desp;~te symptomatic 
recovery was associated with any of the chronicity parameters such a'., age at first de- 
pressive episode, length of illness, number of depressive episodes, ".otal ~.'!aration of being 
dep~,~ssed, duration of feeling well between episodes, age at index episode, and duration 
of iadex episode. 
Sashidharan et al. (1984) found that a shorter duration of index epis.~ae was associated 
with DST nonsuppression in the absence of age, gender, polarity, and ~everity differences 
between the suppressors and nonsuppressors. Lenox et al. (1985) reporte~ a trend for 
nonsuppressors to have a significantly longer duration index epis~ Jle ~nd length of illness 
and a significantly longer length of ilmess in noncon,rerters. ~-~ eve;r, age, severity, and 
clinical recovery represented methodological difficulties in that study. Finally, Meador- 
Woodruff et al. (1987) found no significant correlatio~.~i between a variety of chronicity 
parameters and pretreatment POst-DST plasma cortis~.~l levels. These s~udies examined 
the relationship between DST status and chronicity parameters prior to treatment. We ~,re 
no~: aware of other studies that have exmnined this relationship durir, g and after treatment 
in a controlled fashion. In fact, chronicity parameters are more liXely to be associated 
with the process of neuroendocrine recovery from rather than with the onset of an episode. 
In this report, we studied the effect of the number of depressive episodes on DST 
status during the course of an index depressive episode. We tested the hypothesis that 
patients with a higher number of depressive episodes continued to have higher post-I~.ST 
plasma cortisol levels at the conclusion of treatment. The relationship between the n~mber 
of depressive episodes and other phenomenological aspects of depressive illness was also 
examined. 
Methods 
Sixty-four patients with major depressive disorder, endogenous subtype, met inclusion 
criteria for this study. These patients were seen at the Clinical Studies Unit of the Michigan 
Depression Program. Inclusion criteria were (I) an RDC diagnosis of major depressive 
disorder, endogenous subtype (Spitzer et al. 1977); (2) a Hamilton score for depression 
equal to or higher than 15; (3) absence of physical illness or technical_ exclusion criteria 
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that invalidate DST results; and (4) a plasma postdexamethasone level higher than 5 
ixg/dl. All patients u~:lerwent a comprehensive diagnostic evaluation by two clinicians 
using '.an unstructured interviewed. They all underwent a structured interview by a trained 
research staff m~:mber using the Schedule for Affective Disorders and Schizophrenia 
(SADS) (Spitze~ and Endicott 1975). Past medical records were reviewed, whenever 
possible, to cc, nfirm the longitudinal course of illness. Diagnosis was made by consensual 
agreement of two clinicians involved in treating the patient. A physical examination and 
full ~aboratory work-up were conducted. 
Pa~:ients had a baseline 1 mg dexamethasone suppression test (Carroll et al. 1981) at 
fi~e end of the drug-free period which lasted for 10-14 days. Serial DSTs were administered 
during the course of treatment. Blood sample~ were drawn for plasma cortisol leve! 
determination at 8 AM, 4 PM, and 11 PM. The maximum value of the three samples was 
used, usually the 4 Pm value. Plasma samples were frozen immediately at -70°{2 until 
assayed using a modification of Murphy's competitive protein-binding assay (Murphy 
1967). 
A baseline 17-item Hamilton Rating Scale for Depression (HRSD) (Hamilton 1960) 
was con~?leted at the end of the drag-free period. Serial Hamilton scores, obtained during 
the course of treatment, were rated by the patient's same primary psychiatrist, who was 
blind to the DST results, and coincided with the DST. 
Biological therapies entailed tricyclic antidepressants (TCA), monoamine oxidase in- 
hibitors (MAOI), electroconvulsive ~erapy (ECT), lithium carbonate, or a combination 
of these therapies. Choice of the morality of m:a~ment was based on clinical considerations 
of each subject. All patients rece;,ved adequate biological treatment. A clinically favorable 
outcome was operationally defined as having a Hamilton depression score :~,Jwer than 10 
and less than half the original score at the start cf the study. This point in tim~ ~,as also 
operationally defined as the point of conclusion of treatment. 
Patients were categorized, based on the number of depressive er, hodes, into three 
groups. Group I (acute): one depre~ h,e episode, Group II (moderately chronic): two to 
four depressive episodes, Group IL .,severely chronic): five or more depressive episodes. 
Length of index depressive epic,ode was operationally defined as number of weeks 
depressed before hospitalization p]as number of weeks of hospitalizations until treatment 
was concluded. Age of first depressive episode was defined as age (in years) when the 
patient had a depressive episode that apparently met criteria for a major depressive episode, 
whether or not treatment was sought. This was retrospectively determined from the history, 
based on the clinician's best judgment and records whenever available, but no reliability 
studies were conducted. 
One-way analysis of variance (ANOVA) was conducted [or comparison of a variety 
of clinical parametric variables across the three groups. A X2-test was used for comparing 
the dis~bution of categorical variab!es. Group comparison was conducted prior to, at 
two time-points during the course of, and at the conclusion of treatment. Logarithmic 
transformation of raw data was used in the statistical analy$~s when indicated. 
Results 
Sixty-four patients (21 men, 43 women) had a mean age at index episode of 56.3 
(-+ 14.3) years, HRSD 24.7 __. 6.2, age at first depressive episode 41.2 (.+ 14.9) 
years, and mean length of index episode 40.1 _ 32.4 weeks. The mean pretreatment 
post-DST cortisol level was 13.1 (.+ 6.3) Ixg/dl. This cortisol level showed gradual 
decrease over the course of treatment (7.6 _+ 5.9 to 6.1 .+ 4.6 to 5.8 .+ 5.6 p,g/dl 
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Table t. Characteristics of ,~dl Subjects and Subject~ with Favorable Outcome According to 
"~eir ~)istribution Acros~ the Three Groups 
Group l l I  
Group I Group H (5 or more 
Para,~eter ~,! episode) (2-~ episodes) episodes) Statistic 
All sebjects 
n =  16 n = 25 n = 2 3  
P 
Age 54.5 ( ±  15.2) 58.3 ( ±  13.8) 55. ~7, ( ±  14.7) F = 0.397 N.S. 
Gender M = 5, F -- !1 M -- 11, F -- 14 M -- 5, F -- 18 X 2 -- 2.716 N.S. 
Polarity UP = 15, BP -- 1 UP = 22, BP = 3 UP = 8, BP = |5  X 2 = 21.86 0.001 
Severity (HRSD) 2 ~ 9  ( ±  7.3) 25.3 ( ±  5.3) 23.4 (.4. 6.3) F = 0.914 N.S. 
Post-DST cortisol 1 2 . 3 ( ±  4.8) 1 1 . 8 ( ±  5.3) 15.1 ~.± 7.8) F -- 1.812 N.S. 
Psychotic depression N = 5 N = 7 N = 4 X 2 = 3.39 N.S. 
Subjects with favorable outcome 
n = 13 n = 20 n =  19 
Age 55.5 ( ±  15.6) 62.4 ( -  10.9) 55.9 ( ±  13.0) F = 1.619 N.S. 
Gender M = 4, F = 9 M = 8, F = 12 M = 13, F = 16 X 2 = 2.813 N.S. 
~Uolerity UP = 12, BP = 1 UP = 17, BP = 3 UP = 6, BP = 13 X 2 = 17.56 0.0005 
~everity (I-IRSD) 25.7 (--- 8.1) 24.9 ( ±  5.9) 23.5 ( ±  6.5) F = 0.528 N.S. 
Post-DST cortisol 12.6 ( ±  4.6) !1.9 ( ±  5.9) 13.7 (__. 6.1) F = 0.521 N.S. 
Values ate means ± SD. 
LIP = unipolar; BP = bipolar. 
at the conclusion of treatment). Forty-five patients had unipolar (UP) and 19 patients 
had bipolar (BP) depression. Of these 19 bipolar patients, 9 l,ad a diagnosis of 
"probably bipolar-MY The general characteristics of patients according to their group 
distribution are summarized in Table 1. 
Considering all patients, there were no group differences in severity and POst-DST 
cortisol levels px~or to, at two time points during the course of, or at the end of treat- 
ment. Considering only patients with favorable clinical outcome in each of the three 
groups, there were no group differences in HRSD scores and POst-DST co~so! level~ 
before and at two time points during the course of treatment. H~weve~, at the conclu- 
sion of treatment, there were statistically significant group d~eren¢~ m post-DST plasma 
cortisol levels (Group I 2.8 -+ 1.8, Gloup II 5.3 _~ 5.1, G~v~; HI 7.0 _- 5.5 ttg/dl; 
F ffi 3.19, df ffi 2,48, p < 0.05) in the abse,~ce of diff(~e~lces in HRSD scor~.~. 
Cortisol level differences were mainly between Gr~ps  I and 11[ (F = 6.38, df = 29, 
p < 0.01). This was also true using log-tr~'~stbnned data (~:igures 1 and 2). By clas- 
sifying improved patients within each ~n'~Jup in~ s ~ s s ~ ) r s  versus nonsuppressors, 
there was a trend towards significance (3/13 versus 8/20 v~rsus 11/18, X 2 = 4.58, df 
= 2, p < 0.10), and a significantly higher num~e~ of nonsuppressors in Group ilI 
0 ~, compared to Group I (X 2 = 4.41, df = 1, p < C~ ~.). Retrospective analysis of these 
patients with favorable clinical outcome showed ~o group differences in age at index 
episode, gender distribution, or severity: however, polarity dis~bution was signifi- 
cantly different (Table 1). 
A proportionately equal number of patients in the three groups ~ , !  a favorable clinical 
outcome: Group I 13/16 versus Group lI 15/20 versus Group III 18/22; i.e., the number 
of depressive episodes did not predict clinical recovery (X 2 = 0.54, df - 2, p = NS). 
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Figure I. Conisol levels over the course of treatment of the three groups. No group differer~ces were observed 
at all time points when all subjects were considered, improved subjects showed group differences only at 
the conclusion of treatment. * p < 0.,(,/5. 
38.87, Group lI 46.00 + 32.00, Group III 27.44 _ 25.54 (F  = 2.41, df  = 2,45, p 
< 0.10). Log-transformed data showed statistically significant group differences (F  = 
3.3, df  = 2,45, p < 0.04) with the severely chronic group having a shorter duration of  
index episode than the other two groups. The mean age (years) at first depressive episode 
was as follows: Group 1 54.5 "+" 15.21, Gr II 42.87 _+ 14.61, Gr III 36.21 ± 14.03 (F  
= 7.46, df = 2,60, p = 0.001) with the severely chronic group having a younger age 
of onset. 
Comparison between th~, UP and BP patients before treatment, irrespective of  their 
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Figure 2. Hamilton scores for depression over the course of treatment of the three groups. No group differences 
were observed at all time points both for all subjects and improved s~,~bjects. 
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group distribution, showed theft UPs had significantly higher HRSD scores (26.0 _+ 6.3 
versus 21.76 _+ 4.7, t = 2.63, df = 62, p < 0.01) whereas BPs had a significantly 
higher number of depressive episodes (6.31 _ 2.7 versus 3.0 _+ 2.4, t = 4.64, df = 
62, p < 0.001), in absence of differences in clinical outcome (X 2 = 1.19, df = 1, p 
= NS), age at first depressive episode (40.4 _ 15.3 versus 38.2 _ 13.4, t = 0..51, df 
= 45, p NS), age at index episode (57.5 _+ 14.4 venus 5~.6 + 14.1. t ,J.97, df 
= 62, p = NS), and pretreatment po,:t-DST cortisol levels (13.2 4- 5.4 versus 12.8 _+ 
8. I, t = 0.21, df = 62, p = NS). Finally, comparison between patients with favorable 
outcome and those with unfavorable outcome before treatment, irrespective of their group 
distribution, showed no differences in pretreatment post..DST plasma cortisol levels (12.7 
"4- 5.6 versus 14.6 _ 8.8, t = 0.916, df = 62, p = NS), in severity (24.5 _ 6.1 
versus 25.66 _+ 6.8, t = 0.55, df = 62, p = NS), in gender distribution (X 2 = 1.97, 
df = 1, p = NS), or in polarity (X z = 1.19, df =- 1, p = NS). However, patients with 
favorable clinical outcome had a significantly higher mean age at index episode (58.3 -+ 
11 i3.1 versus 47.66 :~- 16.6, t = 2.4, df = 62, p < 0.G~); i.e., older age predicted better 
outcome. 
Discussion 
In this study, we exea-nined the DST normalization process and its relationship to a number 
of chronicity parameters in 64 patients with major depressive disorder. Phenomenological 
correlates of multij~:city of depressive episodes were also examined. Patients with a 
higher number of depressive episodes had significantly higher post-DST cortis:~l levels 
despite clinical recovery. Though there were no group differences in age, gender distri- 
bution, severity, or pretreatment post-DST plasma cortisol levels, there was a higher 
number of bipolar patients in Group III. 
We believe this is the first study to document such a high incidence Of nonsuppression 
among recovered patients with a high number of depressive episodes. The absence of a 
relationship between pretreatment post-DST cortisol levels and number of depressive 
episodes is consistent with earlier report~ by Meatier-Woodruff et al. (1987) and Lenox 
et al. (1985). These results are along the same lines as those of Lenox et al. regarding 
a significantly longer length of illness in nonconverters, though that study did not control 
for recovery. 
Dexamethasone nonsuppression is reportedly state dependent and DST normalization 
is closely associated with clinical recovery, yet, several lines of evidence suggest that 
this may not be strictly so. First, DST normalization occurs prior to symptomatic recovery 
(Gerken et al. 1985). Second, our results, together with those of Targum (1983), Pa- 
pakostas et al. (1981), Holsboer et al. (1982), and Greden et al. (1983), show that a 
number of patients maintain a nonsz,;~pressive status despite clinical improvement. Third, 
Holsboer et al. (1983) showed that -~onsuppression heralded clinical symptomatic relapse. 
These studies suggest the existeace of a temporal lag between endocrine abnormalities 
a,~d clinical symptomatoIog% R is likely that some of our patients who maintained a 
nonsuppre,~,,or status at the time of recovery converted later into suppressors; it would 
be of interest to find out how long it took them to normalize. We propose that delay in 
the endo~f~ne recovery could be a correlate of chronicity of dep~ssive illness. 
Pol~,i.:y distribution among the groups was different and could be a confounding 
var~b~e, however, several points suggest other~vise. First, 9 o~ the 19 bipolar patients 
in this study carried a "probable bipolar I1" diagnosis. This could have contributed to a 
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seeming!y un~.ven d~stribution in polarity. Second, post-DST cortisol levels of unipolars 
and bipolars were not different. This is consistent with a study by Zisook et al. (1985) 
(and four other studies cited therein) who found no difference in post-DST coW, sol levels 
between unipolar and bipolar depressed patients using a standard 1 nag DST. Therefore, 
it is unlikely that bipolar patients contributed to higher post-DST cortisol levels. Third, 
given the phenomenology of bipolar disorder (Goodwin and Jamison 1984), 25%-30% 
of the patients diagnc, sed as unipol~s, on the basis of having a first depressive episode, 
would later develop a bipolar disorder. Collectively, these points argt~e that the differences 
in cortisol levels were mainly due tG~:he effect of the number of episodes. 
Keller et al. (1981) underlined the theoretical notion that predictors of recovery are 
different from those of relapse, and suggested that the duration of index episode predicts 
recovery, whereas the number of depressive episodes predicts relapse. Our results are in 
agreement with those of Keller et al. (1981, 1982a,b). In this study, a proportionately 
equal number of patients recovered in each group, i.e., the number of depressive episodes 
did not predict recovery. Earlier reports suggest that persistence of DST nonsuppression 
predicted a higher relapse rate (Targum 1983). In this study, nonsuppression, and con- 
sequently higher likelihood for relapse, was associated with a higher number of depressive 
episodes. Comparison between patients with favorable and those with poor outcome 
showed that older age predicted favorable outcome; otherwise, polarity, gender, severity, 
and post-DST cortisol levels did not predict outcome. These results are in partial a~mement 
with those of Keller et al. (1981) regarding age, but not polarity or severity. The shorter 
length of index episode and younger age at onset observed in Group III could have been 
confounded with polarity. However, decrease in cycle length as a function of episode 
number was observed both in unipolar and bipolar patients (Zis and Goodwin 1979; Zis 
et al. 1980; Keller and Shapiro 1981). 
In summary, this study shows that patients with a higher r~urr :~er of depressive episodes 
maintain higher post-DST cortisoi levels despite sy,,nptomat;,: recovery aad suggests the 
existence of a temporal lag between symptomatic and neumendoerine recovery. These 
results require replication in prospectively designed studies that would, hopefully, not be 
confounded with polarity, and would explore other aspects of the relationship between 
various chronicity parameters and HPA axis reguh:tion in depressive disorders. 
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